Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

Turcot syndrome, Microsatellite Instability

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Carcinoma, Renal Cell

Biliary Tract Neoplasms, Digestive System Diseases

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

Carcinoma, Renal Cell

Microsatellite-stable Colorectal Cancer

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Leukemia, Myelodysplastic Syndromes

Colonic Neoplasms

Esophageal Neoplasms

Multiple Myeloma

Brain Neoplasms, Carcinoma, Renal Cell

Genital Neoplasms, Female, Neuroendocrine Tumors

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung

Melanoma, Skin Neoplasms

Lung Diseases, Interstitial

Carcinoma, Non-Small-Cell Lung

Urinary Bladder Neoplasms

Carcinoma, Merkel Cell

Neoplasm Metastasis, Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Uveal Melanoma

Advanced Renal Cell Carcinoma

Turcot syndrome, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Lung Neoplasms

Locally Advanced Solid Tumor

Kidney Neoplasms

Lymphoma, Large B-Cell, Diffuse

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Basal Cell

Brain Neoplasms, Melanoma

Melanoma, Skin Neoplasms

Head and Neck Neoplasms

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Advanced Biliary Tract Cancer(BTC)

Primary Central Nervous System Lymphoma (PCNSL)

Neoplasm Metastasis

Squamous Cell Carcinoma of Head and Neck

Clinical Trials

TAPUR

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

EXACT

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

NICHE

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

MOST-CIRCUIT

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Neo IRENIE

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

G360-IIT

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

METIMMOX

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

ARCITECT

NEOREM-NEO-1

TORCH-OPTIMA

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

ECTOP-1036

CD8 PET Imaging in Metastatic Solid Tumours

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

COMBI-TED

NEON

ABC-X

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

NeoRelapse

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NOBLE

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

CANOPY

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer